Developer docs
API playgroundTry for free, no card

Search company profiles

ARK Diagnostics

Full company profile

uuid0008swu

Namestring
ARK Diagnostics
Websiteurl
ark-tdm.com
Company typeenum
Private
Founded yearint
2003
Descriptiontext

ARK Diagnostics designs, manufactures, and distributes in vitro diagnostic products, with a portfolio centered on diagnostic assays used for therapeutic drug monitoring (TDM). Founded in 2003 and headquartered in Fremont, California, the company develops assays that enable healthcare providers, hospitals, and clinical laboratories to measure and monitor drug levels in patients, supporting personalized medicine and precision dosing workflows. The core technology is chemistry-based in vitro diagnostic assays rather than instrumented platforms, and the company operates within the global TDM market valued at approximately $1.87 billion in 2024 with a 3.92% CAGR projection to ~$2.75 billion by 2034.

The company's revenue model is based on the sale of diagnostic assay products (test kits) to its healthcare and life sciences customer base, with pricing not publicly disclosed. Its go-to-motion targets hospital laboratories and reference labs requiring precision dosing tools, with no AI/ML or software-as-a-service component evident. Prior to October 2025, ARK was majority-owned by South Korean conglomerate Soulbrain Holdings; that month ARCHIMED Diagnostics acquired a 60% controlling stake at a ~$428 million valuation, with stated intent to fund product development, market expansion, and operational scale. Earlier angel capital from Sand Hill Angels (2009, 2012) rounds are also documented.

Short descriptiontext

ARK Diagnostics designs, manufactures, and distributes in vitro diagnostic assays for therapeutic drug monitoring, serving hospitals, clinical laboratories, and healthcare providers seeking precision dosing and personalized medicine tools. Founded in 2003, the Fremont, CA-based company operates within the global TDM market.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersFremont, United States
HQ citystring
Fremont
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
therapeutic drug monitoring, diagnostic assays, in vitro diagnostics, clinical diagnostics, precision dosing
Industry1 code
PRIMARYHLAFAMAF
Toxicology & Therapeutic Drug Monitoring Laboratories
NAICS code1 code
  • In-Vitro Diagnostic Substance Manufacturing325413
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
In Vitro Diagnostics
Revenue model1 record
1Diagnostic Assay Products
TypeHardware Sales
Description

ARK Diagnostics develops and sells diagnostic assay products, likely generating revenue through the sale of diagnostic test kits and related products for therapeutic drug monitoring.

scoperesearch.co
Cost components5 values
Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

ARK Diagnostics designs, manufactures, and distributes in vitro diagnostic assays focused on therapeutic drug monitoring (TDM). Its products enable healthcare providers and clinical laboratories to measure drug levels in patients, supporting precision dosing and personalized medicine.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Global therapeutic drug monitoring market growing at 3.92% CAGR, projected to reach $2.75 billion by 2034
Product overview1 text field

ARK Diagnostics is a developer of diagnostic assays focused on therapeutic drug monitoring (TDM). The company's product portfolio centers on diagnostic assays that enable healthcare providers to measure and monitor drug levels in patients, supporting personalized medicine approaches and precision dosing. The company operates in the broader therapeutic drug monitoring market, which was valued at approximately USD 1870.56 million in 2024 and is forecasted to reach USD 2747.66 million by 2034.

Product and service1 record
1Diagnostic Assays
CategoryIn Vitro Diagnostics / Therapeutic Drug Monitoring
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Soulbrain Holdings
Strategic tierCoreTypeOthersAnnounced on2025-10-01
Description

Soulbrain Holdings, a South Korean company, sold its 60% controlling stake in ARK Diagnostics to ARCHIMED Diagnostics as part of a carve-out transaction valued at approximately $428 million.

globallegalchronicle.com
Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

DiaSorin is a specialty IVD company focused on immunodiagnostics and molecular diagnostics, with comparable scale and channel profile to ARK and overlapping specialty assay development.

TypeBroad incumbent
Description

Siemens Healthineers' Atellica and ADVIA Centaur systems include therapeutic drug monitoring assays as part of their integrated immunoassay/clinical chemistry offerings to large hospital systems.

3Beckman Coulter (Danaher)
TypeBroad incumbent
Description

Beckman Coulter (a Danaher operating company) manufactures automated IVD chemistry and immunoassay systems with TDM-relevant assays, competing with ARK for placement on large hospital and reference-lab platforms.

TypeBroad incumbent
Description

Thermo Fisher (including its Binding Site and specialty diagnostics segments) is a diversified IVD manufacturer serving clinical and research labs, with TDM-related reagents and immunoassay products competing with ARK's portfolio.

TypeBroad incumbent
Description

Roche operates one of the broadest IVD portfolios globally, including therapeutic drug monitoring assays integrated into its cobas automated chemistry/immunoassay platforms used by hospitals and reference labs.

TypeDirect peer
Description

Saladax develops immunoassays specifically for therapeutic drug monitoring of antipsychotics and other drugs — the closest direct competitor to ARK's TDM-focused assay portfolio, targeting the same clinical customers.

TypeDirect peer
Description

QIAGEN develops molecular and immunoassay diagnostic products for clinical and research labs, with a similar specialty-IVD commercial model and customer overlap in hospital and reference laboratories.

TypeDirect peer
Description

Hologic is a specialty diagnostics company whose clinical diagnostics franchise includes assay development for women's health and infectious disease, with comparable specialty-IVD manufacturing and channel characteristics to ARK.

TypeDirect peer
Description

Bio-Rad is a specialty IVD manufacturer with clinical chemistry and immunoassay products; its Life Science and Clinical Diagnostics segments overlap with ARK's reagent/assay manufacturing business model and customer base.

10Abbott Diagnostics
TypeBroad incumbent
Description

Abbott's ARCHITECT and Alinity platforms include TDM assays alongside a much broader IVD menu; competes with ARK for hospital and reference-lab test volume on automated chemistry/immunoassay systems.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ARK Diagnostics

In Vitro Diagnosticsark-tdm.com

ARK Diagnostics designs, manufactures, and distributes in vitro diagnostic assays for therapeutic drug monitoring, serving hospitals, clinical laboratories, and healthcare providers seeking precision dosing and personalized medicine tools. Founded in 2003, the Fremont, CA-based company operates within the global TDM market.

What ARK Diagnostics does

ARK Diagnostics designs, manufactures, and distributes in vitro diagnostic products, with a portfolio centered on diagnostic assays used for therapeutic drug monitoring (TDM). Founded in 2003 and headquartered in Fremont, California, the company develops assays that enable healthcare providers, hospitals, and clinical laboratories to measure and monitor drug levels in patients, supporting personalized medicine and precision dosing workflows. The core technology is chemistry-based in vitro diagnostic assays rather than instrumented platforms, and the company operates within the global TDM market valued at approximately $1.87 billion in 2024 with a 3.92% CAGR projection to ~$2.75 billion by 2034.

The company's revenue model is based on the sale of diagnostic assay products (test kits) to its healthcare and life sciences customer base, with pricing not publicly disclosed. Its go-to-motion targets hospital laboratories and reference labs requiring precision dosing tools, with no AI/ML or software-as-a-service component evident. Prior to October 2025, ARK was majority-owned by South Korean conglomerate Soulbrain Holdings; that month ARCHIMED Diagnostics acquired a 60% controlling stake at a ~$428 million valuation, with stated intent to fund product development, market expansion, and operational scale. Earlier angel capital from Sand Hill Angels (2009, 2012) rounds are also documented.

ARK Diagnostics firmographics

Firmographics
Name
ARK Diagnostics
Website
https://ark-tdm.com
Company type
Private
Founded year
2003
Operating status
Acquired
Headcount range
51–100 employees
Short description
ARK Diagnostics designs, manufactures, and distributes in vitro diagnostic assays for therapeutic drug monitoring, serving hospitals, clinical laboratories, and healthcare providers seeking precision dosing and personalized medicine tools. Founded in 2003, the Fremont, CA-based company operates within the global TDM market.
Ownership category
akta.pro rank

ARK Diagnostics industry classification

Industry
Product category
In Vitro Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAFAMAF
Toxicology & Therapeutic Drug Monitoring Laboratories

Keywords

  • Therapeutic drug monitoring
  • Diagnostic assays
  • In vitro diagnostics
  • Clinical diagnostics
  • Precision dosing

Where ARK Diagnostics is headquartered

Location

Headquarters

HQ city
Fremont
HQ country
United States
HQ region
North America

Markets served

ARK Diagnostics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Diagnostic Assay Products: ARK Diagnostics develops and sells diagnostic assay products, likely generating revenue through the sale of diagnostic test kits and related products for therapeutic drug monitoring.

ARK Diagnostics product offering

Product offering

Core offering

ARK Diagnostics designs, manufactures, and distributes in vitro diagnostic assays focused on therapeutic drug monitoring (TDM). Its products enable healthcare providers and clinical laboratories to measure drug levels in patients, supporting precision dosing and personalized medicine.

Product overview

ARK Diagnostics is a developer of diagnostic assays focused on therapeutic drug monitoring (TDM). The company's product portfolio centers on diagnostic assays that enable healthcare providers to measure and monitor drug levels in patients, supporting personalized medicine approaches and precision dosing. The company operates in the broader therapeutic drug monitoring market, which was valued at approximately USD 1870.56 million in 2024 and is forecasted to reach USD 2747.66 million by 2034.

Differentiator

Problem solved

Functional benefit

Products and services

  • Diagnostic Assays

Quantifiable outcome

  • Global therapeutic drug monitoring market growing at 3.92% CAGR, projected to reach $2.75 billion by 2034

Companies that use ARK Diagnostics

Customer profile

Segments1 record

Ideal customer profiles1 record

ARK Diagnostics technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

ARK Diagnostics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Soulbrain HoldingscoreOthers · 1 October 2025Soulbrain Holdings, a South Korean company, sold its 60% controlling stake in ARK Diagnostics to ARCHIMED Diagnostics as part of a carve-out transaction valued at approximately $428 million.

Scale indicators3 records

Recent moves8 records

Expansion highlights4 records

ARK Diagnostics competitors and assessment

Company assessment

Direct peers

  • DiaSorin: DiaSorin is a specialty IVD company focused on immunodiagnostics and molecular diagnostics, with comparable scale and channel profile to ARK and overlapping specialty assay development.
  • Saladax Biomedical: Saladax develops immunoassays specifically for therapeutic drug monitoring of antipsychotics and other drugs — the closest direct competitor to ARK's TDM-focused assay portfolio, targeting the same clinical customers.
  • QIAGEN: QIAGEN develops molecular and immunoassay diagnostic products for clinical and research labs, with a similar specialty-IVD commercial model and customer overlap in hospital and reference laboratories.
  • Hologic: Hologic is a specialty diagnostics company whose clinical diagnostics franchise includes assay development for women's health and infectious disease, with comparable specialty-IVD manufacturing and channel characteristics to ARK.
  • Bio-Rad Laboratories: Bio-Rad is a specialty IVD manufacturer with clinical chemistry and immunoassay products; its Life Science and Clinical Diagnostics segments overlap with ARK's reagent/assay manufacturing business model and customer base.

Broad incumbents

  • Siemens Healthineers: Siemens Healthineers' Atellica and ADVIA Centaur systems include therapeutic drug monitoring assays as part of their integrated immunoassay/clinical chemistry offerings to large hospital systems.
  • Beckman Coulter (Danaher): Beckman Coulter (a Danaher operating company) manufactures automated IVD chemistry and immunoassay systems with TDM-relevant assays, competing with ARK for placement on large hospital and reference-lab platforms.
  • Thermo Fisher Scientific: Thermo Fisher (including its Binding Site and specialty diagnostics segments) is a diversified IVD manufacturer serving clinical and research labs, with TDM-related reagents and immunoassay products competing with ARK's portfolio.
  • Roche Diagnostics: Roche operates one of the broadest IVD portfolios globally, including therapeutic drug monitoring assays integrated into its cobas automated chemistry/immunoassay platforms used by hospitals and reference labs.
  • Abbott Diagnostics: Abbott's ARCHITECT and Alinity platforms include TDM assays alongside a much broader IVD menu; competes with ARK for hospital and reference-lab test volume on automated chemistry/immunoassay systems.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

ARK Diagnostics social profiles

Digital presence

ARK Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ARK Diagnostics leadership team

Management profile

Number of profiles

Profiles1 record

ARK Diagnostics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ARK Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ARK Diagnostics

What does ARK Diagnostics do?

ARK Diagnostics designs, manufactures, and distributes in vitro diagnostic assays focused on therapeutic drug monitoring (TDM). Its products enable healthcare providers and clinical laboratories to measure drug levels in patients, supporting precision dosing and personalized medicine.

Is ARK Diagnostics a public or private company?

ARK Diagnostics is a private company. It is classified as private equity controlled and is currently acquired.

When was ARK Diagnostics founded?

ARK Diagnostics was founded in 2003. It employs 51 to 100 people.

Where is ARK Diagnostics based?

ARK Diagnostics is headquartered in Fremont, United States, in the North America region.

How does ARK Diagnostics make money?

One revenue line is on record: diagnostic Assay Products.

Who are ARK Diagnostics's main competitors?

Direct peers on record are DiaSorin, Saladax Biomedical, QIAGEN, Hologic and Bio-Rad Laboratories. Broad incumbents are Siemens Healthineers, Beckman Coulter (Danaher), Thermo Fisher Scientific, Roche Diagnostics and Abbott Diagnostics.

Does ARK Diagnostics have an API?

No public API is recorded for ARK Diagnostics.

What industry is ARK Diagnostics in?

ARK Diagnostics's product category is In Vitro Diagnostics. Its primary akta.pro industry code is HLAFAMAF, Toxicology & Therapeutic Drug Monitoring Laboratories. Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
DechertSector Focus: AI-Driven Tech, Healthcare and Financial Services Lead DealmakingA survey of private equity professionals reveals that life sciences/healthcare and technology are the top sectors for investment over the next 24 months, with 75% and 74% of respondents planning to invest in each respectively. Preqin data shows sector specialist funds have outperformed generalist funds, posting median DPI of 136.7% versus 130% for 2012-2015 vintages, driving LPs to increasingly prefer specialized strategies. Notable recent deals include ARCHIMED's carve-out of ARK Diagnostics at a $428 million valuation and Morgan Stanley Capital Partners' sale of Clarity Software Solutions to mPulse.ScoperesearchARK Diagnostics AcquiredIn October 2025, ARCHIMED Diagnostics acquired a 60% stake in ARK Diagnostics, a developer of diagnostic assays, from South Korean company Soulbrain Holdings. The deal values ARK at approximately $428 million and aims to enhance ARK's product development, market expansion, and operational scale.ArchimedARCHIMED Diagnostics closes its acquisition of ARK Diagnostics, a global leader in disease and drug monitoring & detectionARCHIMED Diagnostics has completed its acquisition of ARK Diagnostics from Soulbrain Holdings, involving a 60% stake valued at $428 million. This acquisition enhances ARK's position as a global leader in disease and drug monitoring diagnostics and includes a joint venture to accelerate product development.